Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.

about

Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.

Item

http://www.wikidata.org/entity/Q48237896

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Persistently low lymphocyte co ...... with longer overall survival.

@en

Persistently low lymphocyte co ...... with longer overall survival.

@nl

type

Item

label

Persistently low lymphocyte co ...... with longer overall survival.

@en

Persistently low lymphocyte co ...... with longer overall survival.

@nl

prefLabel

Persistently low lymphocyte co ...... with longer overall survival.

@en

Persistently low lymphocyte co ...... with longer overall survival.

@nl

P1476

Persistently low lymphocyte co ...... with longer overall survival.

@en

P2093

Aaron Polliack

http://www.w3.org/2001/XMLSchema#string

Andrei Braester

http://www.w3.org/2001/XMLSchema#string

Ariel Aviv

http://www.w3.org/2001/XMLSchema#string

Lev Shvidel

http://www.w3.org/2001/XMLSchema#string

N Ariela Arad

http://www.w3.org/2001/XMLSchema#string

Naomi Rahimi-Levene

http://www.w3.org/2001/XMLSchema#string

Neta Goldschmidt

http://www.w3.org/2001/XMLSchema#string

Osnat Bairey

http://www.w3.org/2001/XMLSchema#string

Riva Fineman

http://www.w3.org/2001/XMLSchema#string

Rosa Ruchlemer

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.

Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.

Unbiased Recursive Partitioning: A Conditional Inference Framework

P304

128-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2444

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28639416

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte